default author photo

Miguel Ángel Vesga

University of the Basque Country - Biocruces Bizkaia Health Research Institute

SCHOLARLY PAPERS

1

DOWNLOADS

32

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

A Phase I, Dose-Escalation Clinical Trial to Evaluate the Safety of Infusing Natural Killer Cells as Adoptive Therapy in COVID-19: Release

Number of pages: 26 Posted: 14 Jun 2024
Hospital Universitario La Paz, Universidad de Alicante - Alicante’s Institute for Health and Biomedical Research (ISABIAL), University of the Basque Country - Biocruces Bizkaia Health Research Institute, Health Research Institute Hospital La Fe, Icahn School of Medicine at Mount Sinai - Precision Immunology Institute, Mount Sinai Health System - Icahn School of Medicine, Icahn School of Medicine at Mount Sinai - Precision Immunology Institute, Hospital Universitario La Paz, La Paz University Hospital - Emergency Department and Emergent Pathology Research Group, Centro de Transfusión de la Comunidad de Madrid, University of the Basque Country - Biocruces Bizkaia Health Research Institute, University of the Basque Country - Biocruces Bizkaia Health Research Institute, University of the Basque Country - Biocruces Bizkaia Health Research Institute, Hospital Universitario La Paz - Servicio de Farmacología Clínica, La Paz Institute for Health Research (IdiPAZ), Centro de Transfusión de la Comunidad de Madrid, Centro de Transfusión de la Comunidad de Madrid, La Paz Institute for Health Research (IdiPAZ), Hospital Universitario La Paz, Miguel Hernández University of Elche - Pediatric Hemato-oncology Department, University of the Basque Country - Biocruces Bizkaia Health Research Institute and Hospital Universitario La Paz
Downloads 32 (1,290,922)

Abstract:

Loading...

Cell therapyNatural Killer cellsmicrochimerimsSARS-CoV-2COVID-19Convalescent donorCytokines